Literature DB >> 35715588

Circulating Plasma miRNA Homologs in Mice and Humans Reflect Familial Cerebral Cavernous Malformation Disease.

Abhinav Srinath1, Ying Li1,2, Romuald Girard1, Issam A Awad3, Sharbel G Romanos1, Bingqing Xie4, Chang Chen1,5, Yan Li1,5, Thomas Moore1, Dehua Bi1,6, Je Yeong Sone1, Rhonda Lightle1, Nick Hobson1, Dongdong Zhang1, Janne Koskimäki1, Le Shen7, Sara McCurdy8, Catherine Chinhchu Lai8, Agnieszka Stadnik1, Kristina Piedad1, Julián Carrión-Penagos1, Abdallah Shkoukani1, Daniel Snellings9, Robert Shenkar1, Dinanath Sulakhe5, Yuan Ji1,6, Miguel A Lopez-Ramirez8,10, Mark L Kahn11, Douglas A Marchuk9, Mark H Ginsberg8.   

Abstract

Patients with familial cerebral cavernous malformation (CCM) inherit germline loss of function mutations and are susceptible to progressive development of brain lesions and neurological sequelae during their lifetime. To date, no homologous circulating molecules have been identified that can reflect the presence of germ line pathogenetic CCM mutations, either in animal models or patients. We hypothesize that homologous differentially expressed (DE) plasma miRNAs can reflect the CCM germline mutation in preclinical murine models and patients. Herein, homologous DE plasma miRNAs with mechanistic putative gene targets within the transcriptome of preclinical and human CCM lesions were identified. Several of these gene targets were additionally found to be associated with CCM-enriched pathways identified using the Kyoto Encyclopedia of Genes and Genomes. DE miRNAs were also identified in familial-CCM patients who developed new brain lesions within the year following blood sample collection. The miRNome results were then validated in an independent cohort of human subjects with real-time-qPCR quantification, a technique facilitating plasma assays. Finally, a Bayesian-informed machine learning approach showed that a combination of plasma levels of miRNAs and circulating proteins improves the association with familial-CCM disease in human subjects to 95% accuracy. These findings act as an important proof of concept for the future development of translatable circulating biomarkers to be tested in preclinical studies and human trials aimed at monitoring and restoring gene function in CCM and other diseases.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cerebral cavernous malformations; Genotype; Machine learning; MicroRNA

Year:  2022        PMID: 35715588     DOI: 10.1007/s12975-022-01050-3

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  62 in total

Review 1.  Cavernous angiomas: deconstructing a neurosurgical disease.

Authors:  Issam A Awad; Sean P Polster
Journal:  J Neurosurg       Date:  2019-07-01       Impact factor: 5.115

2.  Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations.

Authors:  Romuald Girard; Maged D Fam; Hussein A Zeineddine; Huan Tan; Abdul Ghani Mikati; Changbin Shi; Michael Jesselson; Robert Shenkar; Meijing Wu; Ying Cao; Nicholas Hobson; Henrik B W Larsson; Gregory A Christoforidis; Issam A Awad
Journal:  J Neurosurg       Date:  2016-08-05       Impact factor: 5.115

3.  Vascular permeability in cerebral cavernous malformations.

Authors:  Abdul G Mikati; Omaditya Khanna; Lingjiao Zhang; Romuald Girard; Robert Shenkar; Xiaodong Guo; Akash Shah; Henrik B W Larsson; Huan Tan; Luying Li; Matthew S Wishnoff; Changbin Shi; Gregory A Christoforidis; Issam A Awad
Journal:  J Cereb Blood Flow Metab       Date:  2015-05-13       Impact factor: 6.200

4.  Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH).

Authors:  Sean P Polster; Ying Cao; Timothy Carroll; Kelly Flemming; Romuald Girard; Daniel Hanley; Nicholas Hobson; Helen Kim; James Koenig; Janne Koskimäki; Karen Lane; Jennifer J Majersik; Nichol McBee; Leslie Morrison; Robert Shenkar; Agnieszka Stadnik; Richard E Thompson; Joseph Zabramski; Hussein A Zeineddine; Issam A Awad
Journal:  Neurosurgery       Date:  2019-04-01       Impact factor: 4.654

5.  Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity.

Authors:  Wan Zhu; Fanxia Shen; Lei Mao; Lei Zhan; Shuai Kang; Zhengda Sun; Jeffrey Nelson; Rui Zhang; Dingquan Zou; Cameron M McDougall; Michael T Lawton; Thiennu H Vu; Zhijian Wu; Abraham Scaria; Peter Colosi; John Forsayeth; Hua Su
Journal:  Stroke       Date:  2017-03-21       Impact factor: 7.914

6.  Quantitative susceptibility mapping as a monitoring biomarker in cerebral cavernous malformations with recent hemorrhage.

Authors:  Hussein A Zeineddine; Romuald Girard; Ying Cao; Nicholas Hobson; Maged D Fam; Agnieszka Stadnik; Huan Tan; Jingjing Shen; Kiranj Chaudagar; Robert Shenkar; Richard E Thompson; Nichol McBee; Daniel Hanley; Timothy Carroll; Gregory A Christoforidis; Issam A Awad
Journal:  J Magn Reson Imaging       Date:  2017-08-09       Impact factor: 4.813

Review 7.  The future of blood-based biomarkers for the early detection of breast cancer.

Authors:  Sau Yeen Loke; Ann Siew Gek Lee
Journal:  Eur J Cancer       Date:  2018-02-06       Impact factor: 9.162

8.  A Roadmap for Developing Plasma Diagnostic and Prognostic Biomarkers of Cerebral Cavernous Angioma With Symptomatic Hemorrhage (CASH).

Authors:  Romuald Girard; Yan Li; Agnieszka Stadnik; Robert Shenkar; Nicholas Hobson; Sharbel Romanos; Abhinav Srinath; Thomas Moore; Rhonda Lightle; Abdallah Shkoukani; Amy Akers; Timothy Carroll; Gregory A Christoforidis; James I Koenig; Cornelia Lee; Kristina Piedad; Steven M Greenberg; Helen Kim; Kelly D Flemming; Yuan Ji; Issam A Awad
Journal:  Neurosurgery       Date:  2021-02-16       Impact factor: 4.654

Review 9.  Cerebral Cavernous Malformation: From Mechanism to Therapy.

Authors:  Daniel A Snellings; Courtney C Hong; Aileen A Ren; Miguel A Lopez-Ramirez; Romuald Girard; Abhinav Srinath; Douglas A Marchuk; Mark H Ginsberg; Issam A Awad; Mark L Kahn
Journal:  Circ Res       Date:  2021-06-24       Impact factor: 23.213

10.  Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.

Authors:  Robert Shenkar; Changbin Shi; Douglas A Marchuk; Issam A Awad; Tania Rebeiz; Rebecca A Stockton; David A McDonald; Abdul Ghani Mikati; Lingjiao Zhang; Cecilia Austin; Amy L Akers; Carol J Gallione; Autumn Rorrer; Murat Gunel; Wang Min; Jorge Marcondes De Souza; Connie Lee
Journal:  Genet Med       Date:  2014-08-14       Impact factor: 8.822

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.